damage, [ii] other circumstances indicating that the applicant is facing financial distress, or [iii] reasonable grounds to believe that the applicant has any deficiency or inappropriateness in operational
. UTILITY PUBLIC COMPANY LIMITED JSP: JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED JTS: JASMINE TECHNOLOGY SOLUTION PUBLIC COMPANY LIMITED JUBILE: JUBILEE ENTERPRISE PUBLIC COMPANY
distress d by 76.0 mil es from J Fin revenue w e same per bles and in er of 2017 e ease 54.5 Company’s crease from emuneration cial statem ht or 2.9 per was 585.2 m ast year. An n in revenu ross margin 350.3
. However, cash flow can still be collected as the Company continuously acquired more distress debt. In the quarter 3-4 of the year 2019. In the past, the Company had bought non-performing loans from
expenses equal to 636.7 million baht, 12.8 % increasing. This is due to the allowance of provision in distress debt management business and personal loan business. Finance Cost The company had total
revenue has continuously grown mainly due to its greater expansion of laboratory scopes of testing and analyzing for agricultural, food, and pharmaceutical associated with continual growing number of
by more efficient management of pharmaceutical supplies. Administrative Expenses During 9M17, administrative expenses increased by 14% yoy due mainly to the increase of headcounts and salary rate in
อร์ตี้ จำกัด (มหาชน) กรุณาระบุเงื่อนไขในการค้นหา ค้นหาบริษัท JP: JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED JSP: บริษัท เจ. เอส. พี. พร็อพเพอร์ตี้ จำกัด (มหาชน) ล้างเงื่อนไข
T.KRUNGTHAI INDUSTRIES PUBLIC COMPANY LIMITED Filing FinancialStatement 56-1 56-2 Ranking TMC T.M.C. INDUSTRIAL PUBLIC COMPANY LIMITED Filing FinancialStatement 56-1 56-2 Ranking TMAN T.Man Pharmaceutical
and PET assets acquired in April 2016. As mentioned previously, financial distress of a PET player in EMEA has created supply tightness in the region, which IVL and other producers are trying to